Inhibitor of apoptosis proteins in hematological malignancies

Leukemia

Volumn 23, Issue 3, 2009, Pages 467-476

  Fulda, S ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; AEG 35156; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BIOLOGICAL MARKER; BORTEZOMIB; CARBANILAMIDE DERIVATIVE; CASPASE; CYTARABINE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EM 1421; IDARUBICIN; INHIBITOR OF APOPTOSIS PROTEIN; LBW 242; LIVIN; LY 2181308; MELPHALAN; PROTEASOME INHIBITOR; PROTEIN INHIBITOR; SALINOSPORAMIDE A; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SERINE PROTEINASE OMI; SM 131; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; X LINKED INHIBITOR OF APOPTOSIS; X LINKED INHIBITOR OF APOPTOSIS ASSOCIATED FACTOR 1;

APOPTOSIS; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOTOXICITY; DISEASE MODEL; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; HEMATOLOGIC MALIGNANCY; HOMEOSTASIS; HUMAN; LEUKEMIA; LEUKEMIA CELL; LEUKEMOGENESIS; LYMPHOMA; LYMPHOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

EID: 62549108186     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.329     Document Type: Review

References (141)

1. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407 770-776.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100 57-70.
3. Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood 2005; 106: 408-418.
4. Schimmer AD. Apoptosis in leukemia: From molecular pathways to targeted therapies. Best Pract Res Clin Haematol 2008; 21: 5-11.
5. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164.
6. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342-348.
7. Taylor K, Micha D, Ranson M, Dive C. Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain. Expert Opin Investig Drugs 2006; 15: 669-690.
8. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-4811.
9. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003; 22: 8543-8567.
10. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007; 39: 1462-1475.
11. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10: 26-35.
12. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163.
13. Riedl SJ, Salvesen GS. The apoptosome: Signalling platform of cell death. Nat Rev Mol Cell Biol 2007; 8: 405-413.
14. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42.
15. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE et al Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 43-53.
16. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007; 12: 1543-1568.
17. Salvesen GS, Duckett CS. IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3: 401-410.
18. Vaux DL, Silke J. IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 2005; 6: 287-297.
19. Damiano JS, Reed JC. CARD proteins as therapeutic targets in cancer. Curr Drug Targets 2004; 5: 367-374.
20. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: Why XIAP is the black sheep of the family. EMBO Rep 2006; 7: 988-994.
21. Shiozaki EN, Shi Y. Caspases, IAPs and Smac/DIABLO: Mechanisms from structural biology. Trends Biochem Sci 2004; 29: 486-494.
22. Chai J, Shiozaki E, Srinivasula SM, Wu Q, Datta P, Alnemri ES et al Structural basis of caspase-7 inhibition by XIAP. Cell 2001; 104: 769-780.
23. Riedl SJ, Renatus M, Schwarzenbacher R, Zhou Q, Sun C, Fesik SW et al Structural basis for the inhibition of caspase-3 by XIAP. Cell 2001; 104: 791-800.
24. Huang Y, Park YC, Rich RL, Segal D, Myszka DG, Wu H. Structural basis of caspase inhibition by XIAP: Differential roles of the linker versus the BIR domain. Cell 2001; 104: 781-790.
25. Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J et al A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 2001; 410: 112-116.
26. Shiozaki EN, Chai J, Rigotti DJ, Riedl SJ, Li P, Srinivasula SM et al Mechanism of XIAP-mediated inhibition of caspase-9. Mol Cell 2003; 11: 519-527.
27. Lu M, Lin S-C, Huang Y, Kang YJ, Rich R, Lo Y-C et al. XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1 dimerization. Mol Cell 2007; 26: 689-702.
28. Hofer-Warbinek R, Schmid JA, Stehlik C, Binder BR, Lipp J, de Martin R. Activation of NF-kappa B by XIAP, the X chromosomelinked inhibitor of apoptosis, in endothelial cells involves TAK1. J Biol Chem 2000; 275: 22064-22068.
29. Levkau B, Garton KJ, Ferri N, Kloke K, Nofer JR, Baba HA et al. xIAP induces cell-cycle arrest and activates nuclear factorkappaB: New survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. Circ Res 2001; 88: 282-290.
30. Lewis J, Burstein E, Reffey SB, Bratton SB, Roberts AB, Duckett CS. Uncoupling of the signaling and caspase-inhibitory properties of X-linked inhibitor of apoptosis. J Biol Chem 2004; 279: 9023-9029.
31. Birkey Reffey S, Wurthner JU, Parks WT, Roberts AB, Duckett CS. X-linked inhibitor of apoptosis protein functions as a cofactor in transforming growth factor-beta signaling. J Biol Chem 2001; 276: 26542-26549.
32. Huang H, Joazeiro CA, Bonfoco E, Kamada S, Leverson JD, Hunter T. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. J Biol Chem 2000; 275: 26661-26664.
33. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700.
34. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K et al. c-IAP1 and c-IAP2 are critical mediators of TNFalpha-induced NF-kappa B activation. J Biol Chem 2008; 283 24295-24299.
35. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA 2008; 105: 11778-11783.
36. Wertz IE, Dixit VM. Ubiquitin-mediated regulation of TNFR1 signaling. Cytokine Growth Factor Rev 2008; 19: 313-324.
37. Xu L, Zhu J, Hu X, Zhu H, Kim HT, LaBaer J et al. c-IAP1 cooperates with Myc by acting as a ubiquitin ligase for Mad1. Mol Cell 2007; 28: 914-922.
38. Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 2001; 276: 3238-3246.
39. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 2000; 10: 1359-1366.
40. Ashhab Y, Alian A, Polliack A, Panet A, Ben Yehuda D. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett 2001; 495 56-60.
41. Chang H, Schimmer AD. Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy. Mol Cancer Ther 2007; 6: 24-30.
42. Vucic D, Deshayes K, Ackerly H, Pisabarro MT, Kadkhodayan S, Fairbrother WJ et al. SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). J Biol Chem 2002; 277 12275-12279.
43. Vucic D, Franklin MC, Wallweber HJA, Das K, Eckelman BP, Shin H et al Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: Implications for Smac-dependent antiapoptotic activity of ML-IAP. Biochem J 2005; 385: 11-20.
44. Sanna MG, da Silva Correia J, Ducrey O, Lee J, Nomoto K, Schrantz N et al. IAP suppression of apoptosis involves distinct mechanisms: The TAK1/JNK1 signaling cascade and caspase inhibition. Mol Cell Biol 2002; 22: 1754-1766.
45. Nachmias B, Ashhab Y, Bucholtz V, Drize O, Kadouri L, Lotem M et al Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: Implications for drug-resistant melanoma. Cancer Res 2003; 63: 6340-6349.
46. Nachmias B, Lazar I, Elmalech M, Abed-El-Rahaman I, Asshab Y, Mandelboim O et al. Subcellular localization determines the delicate balance between the anti- and pro-apoptotic activity of Livin. Apoptosis 2007; 12: 1129-1142.
47. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8: 61-70.
48. O'Connor DS, Wall NR, Porter AC, Altieri DC. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2002; 2: 43-54.
49. Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003; 63: 230-235.
50. Song Z, Yao X, Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 2003; 278: 23130-23140.
51. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC. Therapeutic targeting of the survivin pathway in cancer: Initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 2003; 9: 2683-2692.
52. Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004; 279: 34087-34090.
53. Vaux DL, Silke J. Mammalian mitochondrial IAP binding proteins. Biochem Biophys Res Commun 2003; 304: 499-504.
54. Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X et al. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000; 408: 1008-1012.
55. Huang Y, Rich RL, Myszka DG, Wu H. Requirement of both the second and third BIR domains for the relief of X-linked inhibitor of apoptosis protein (XIAP)-mediated caspase inhibition by Smac. J Biol Chem 2003; 278: 49517-49522.
56. Vande Walle L, Lamkanfi M, Vandenabeele P. The mitochondrial serine protease HtrA2/Omi: An overview. Cell Death Differ 2008; 15: 453-460.
57. Martins LM, Iaccarino I, Tenev T, Gschmeissner S, Totty NF, Lemoine NR et al. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem 2002; 277 439-444.
58. Suzuki Y, Takahashi-Niki K, Akagi T, Hashikawa T, Takahashi R. Mitochondrial protease Omi/HtrA2 enhances caspase activation through multiple pathways. Cell Death Differ 2004; 11: 208-216.
59. Van Loo G, Van Gurp M, Depuydt B, Srinivasula SM, Rodriguez I, Alnemri ES et al. The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity. Cell Death Differ 2002; 9: 20-26.
60. Li W, Srinivasula SM, Chai J, Li P, Wu JW, Zhang Z et al. Structural insights into the pro-apoptotic function of mitochondrial serine protease HtrA2/Omi. Nat Struct Biol 2002; 9: 436-441.
61. Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, Conte D et al. Identification of XAF1 as an antagonist of XIAP anti-caspase activity. Nat Cell Biol 2001; 3: 128-133.
62. Plenchette S, Cheung HH, Fong WG, LaCasse EC, Korneluk RG. The role of XAF1 in cancer. Curr Opin Investig Drugs 2007; 8: 469-476.
63. Arora V, Cheung HH, Plenchette S, Micali OC, Liston P, Korneluk RG. Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J Biol Chem 2007; 282: 26202-26209.
64. Leaman DW, Chawla-Sarkar M, Vyas K, Reheman M, Tamai K, Toji S et al Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis. J Biol Chem 2002; 277: 28504-28511.
65. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007; 131: 669-681.
66. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682-693.
67. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007; 12: 445-456.
68. Gaither A, Porter D, Yao Y, Borawski J, Yang G, Donovan J et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res 2007; 67: 11493-11498.
69. Oost TK, Sun C, Armstrong RC, Al-Assaad AS, Betz SF, Deckwerth TL et al. Discovery of potent antagonists of the anti-apoptotic protein XIAP for the treatment of cancer. J Med Chem 2004; 47: 4417-4426.
70. Bockbrader KM, Tan M, Sun Y. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene 2005; 24: 7381-7388.
71. Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004; 5: 25-35.
72. LaCasse EC, Kandimalla ER, Winocour P, Sullivan T, Agrawal S, Gillard JW et al. Application of XIAP antisense to cancer and other proliferative disorders: Development of AEG35156/GEM640. Ann N Y Acad Sci 2005; 1058: 215-234.
73. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67: 8014-8021.
74. Chang CC, Heller JD, Kuo J, Huang RC. Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci USA 2004; 101: 13239-13244.
75. Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999; 93: 3601-3609.
76. Akagi T, Motegi M, Tamura A, Suzuki R, Hosokawa Y, Suzuki H et al. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 1999; 18: 5785-5794.
77. Morgan JA, Yin Y, Borowsky AD, Kuo F, Nourmand N, Koontz JI et al. Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res 1999; 59: 6205-6213.
78. Varfolomeev E, Wayson SM, Dixit VM, Fairbrother WJ, Vucic D. The inhibitor of apoptosis protein fusion c-IAP2.MALT1 stimulates NF-kappaB activation independently of TRAF1 AND TRAF2. J Biol Chem 2006; 281: 29022-29029.
79. Waldele K, Silbermann K, Schneider G, Ruckes T, Cullen BR, Grassmann R. Requirement of the human T-cell leukemia virus (HTLV-1) tax-stimulated HIAP-1 gene for the survival of transformed lymphocytes. Blood 2006; 107: 4491-4499.
80. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12: 115-130.
81. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131-144.
82. Hasegawa T, Suzuki K, Sakamoto C, Ohta K, Nishiki S, Hino M et al. Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: Up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia. Blood 2003; 101: 1164-1171.
83. Plenchette S, Cathelin S, Rebe C, Launay S, Ladoire S, Sordet O et al Translocation of the inhibitor of apoptosis protein c-IAP1 from the nucleus to the Golgi in hematopoietic cells undergoing differentiation: a nuclear export signal-mediated event. Blood 2004; 104: 2035-2043.
84. Didelot C, Lanneau D, Brunet M, Bouchot A, Cartier J, Jacquel A et al Interaction of heat-shock protein 90 beta isoform (HSP90 beta) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiation. Cell Death Differ 2008; 15: 859-866.
85. De Graaf AO, van Krieken JH, Tonnissen E, Wissink W, van de Locht L, Overes I et al. Expression of C-IAP1, C-IAP2 and SURVIVIN discriminates different types of lymphoid malignancies. Br J Haematol 2005; 130: 852-859.
86. Vallat L, Magdelenat H, Merle-Beral H, Masdehors P, Potocki de Montalk G, Davi F et al. The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays. Blood 2003; 101: 4598-4606.
87. Silva KL, Vasconcellos DV, Castro ED, Coelho AM, Linden R, Maia RC. Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia. Apoptosis 2006; 11: 277-285.
88. Nakagawa Y, Hasegawa M, Kurata M, Yamamoto K, Abe S, Inoue M et al Expression of IAP-family proteins in adult acute mixed lineage leukemia (AMLL). Am J Hematol 2005; 78: 173-180.
89. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S et al Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000; 6: 1796-1803.
90. Carter BZ, Kornblau SM, Tsao T, Wang RY, Schober WD, Milella M et al Caspase-independent cell death in AML: Caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or survivin does not affect cell survival or prognosis. Blood 2003; 102: 4179-4186.
91. Tamm I, Richter S, Scholz F, Schmelz K, Oltersdorf D, Karawajew L et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: Impact on prognosis. Hematol J 2004; 5 489-495.
92. Tamm I, Richter S, Oltersdorf D, Creutzig U, Harbott J, Scholz F et al. High expression levels of X-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 2004; 10: 3737-3744.
93. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C et al. Analysis of human transcriptomes. Nat Genet 1999; 23: 387-388.
94. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006; 5: 1087-1098.
95. Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 2004; 22: 1682-1688.
96. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96: 1921-1925.
97. Balkhi MY, Christopeit M, Chen Y, Geletu M, Behre G. AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation. Exp Hematol 2008; 36: 1455-1466.
98. Troeger A, Siepermann M, Escherich G, Meisel R, Willers R, Gudowius S et al. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica 2007; 92 1043-1050.
99. Troger A, Siepermann M, Mahotka C,Wethkamp N, Bulle H, Laws HJ et al Role of survivin splice variants in pediatric acute precursor B lymphoblastic leukemia. Klin Padiatr 2007; 219: 127-133.
100. Romagnoli M, Trichet V, David C, Clement M, Moreau P, Bataille R et al. Significant impact of survivin on myeloma cell growth. Leukemia 2007; 21: 1070-1078.
101. Che XF, Zheng CL, Owatari S, Mutoh M, Gotanda T, Jeung HC et al. Overexpression of survivin in primary ATL cells and sodium arsenite induces apoptosis by down-regulating survivin expression in ATL cell lines. Blood 2006; 107: 4880-4887.
102. Nakayama K, Kamihira S. Survivin an important determinant for prognosis in adult T-cell leukemia: A novel biomarker in practical hemato-oncology. Leuk Lymphoma 2002; 43: 2249-2255.
103. Wang Z, Sampath J, Fukuda S, Pelus LM. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res 2005; 65: 8224-8232.
104. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M et al Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2777-2783.
105. Choi J, Hwang YK, Sung KW, Lee SH, Yoo KH, Jung HL et al. Expression of livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood 2007; 109: 471-477.
106. Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 998-1006.
107. Pui CH, Behm FG, Downing JR, Hancock ML, Shurtleff SA, Ribeiro RC et al. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 1994; 12: 909-915.
108. Chen CS, Sorensen PH, Domer PH, Reaman GH, Korsmeyer SJ, Heerema NA et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 1993; 81: 2386-2393.
109. Ren Y, Akyurek N, Schlette E, Rassidakis GZ, Medeiros LJ. Expression of Smac/DIABLO in B-cell non-Hodgkin and Hodgkin lymphomas. Hum Pathol 2006; 37: 1407-1413.
110. Fong WG, Liston P, Rajcan-Separovic E, St Jean M, Craig C, Korneluk RG. Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics 2000; 70: 113-122.
111. Ng KC, Campos EI, Martinka M, Li G. XAF1 expression is significantly reduced in human melanoma. J Invest Dermatol 2004; 123: 1127-1134.
112. Byun DS, Cho K, Ryu BK, Lee MG, Kang MJ, Kim HR et al. Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res 2003; 63: 7068-7075.
113. Zou B, Chim CS, Zeng H, Leung SY, Yang Y, Tu SP et al. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. Gastroenterology 2006; 131: 1835-1843.
114. Chen G-H, Lin F-R, Ren J-H, Chen J, Zhang J-N, Wang Y et al. Expression and significance of X-linked inhibitor of apoptosis protein and its antagonized proteins in acute leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006; 14: 639-643.
115. Zent CS, Zhan F, Schichman SA, Bumm KH, Lin P, Chen JB et al. The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype. Leuk Res 2003; 27: 765-774.
116. Zobel K, Wang L, Varfolomeev E, Franklin MC, Elliott LO, Wallweber HJ et al. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem Biol 2006; 1: 525-533.
117. Sun H, Nikolovska-Coleska Z, Lu J, Qiu S, Yang CY, Gao W et al. Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. J Med Chem 2006; 49: 7916-7920.
118. Sun H, Nikolovska-Coleska Z, Chen J, Yang CY, Tomita Y, Pan H et al Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics. Bioorg Med Chem Lett 2005; 15 793-797.
119. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004; 305: 1471-1474.
120. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/ TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002; 8: 808-815.
121. Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 2002; 277: 44236-44243.
122. Yang L, Mashima T, Sato S, Mochizuki M, Sakamoto H, Yamori T et al Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: Therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res 2003; 63: 831-837.
123. Guo F, Nimmanapalli R, Paranawithana S, Wittman S, Griffin D, Bali P et al. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 2002; 99: 3419-3426.
124. Chauhan D, Neri P, Velankar M, Podar K, Hideshima T, Fulciniti M et al. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 2007; 109: 1220-1227.
125. Jia L, Patwari Y, Kelsey SM, Srinivasula SM, Agrawal SG, Alnemri ES et al. Role of Smac in human leukaemic cell apoptosis and proliferation. Oncogene 2003; 22: 1589-1599.
126. Kashkar H, Seeger JM, Hombach A, Deggerich A, Yazdanpanah B, Utermohlen O et al. XIAP targeting sensitizes Hodgkin lymphoma cells for cytolytic T-cell attack. Blood 2006; 108: 3434-3440.
127. Kashkar H, Haefs C, Shin H, Hamilton-Dutoit SJ, Salvesen GS, Kronke M et al. XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells. J Exp Med 2003; 198: 341-347.
128. Yang QH, Du C. Smac/DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of XIAP and livin in HeLa cells. J Biol Chem 2004; 279: 16963-16970.
129. Weisberg E, Kung AL, Wright RD, Moreno D, Catley L, Ray A et al. Potentiation of antileukemic therapies by Smac mimetic, LBW242: Effects on mutant FLT3-expressing cells. Mol Cancer Ther 2007; 6: 1951-1961.
130. Nikolovska-Coleska Z, Xu L, Hu Z, Tomita Y, Li P, Roller PP et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem 2004; 47: 2430-2440.
131. Wang Z, Cuddy M, Samuel T, Welsh K, Schimmer A, Hanaii F et al. Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors. J Biol Chem 2004; 279: 48168-48176.
132. Carter BZ, Gronda M, Wang Z, Welsh K, Pinilla C, Andreeff M et al. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood 2005; 105: 4043-4050.
133. Cillessen SA, Reed JC, Welsh K, Pinilla C, Houghten R, Hooijberg E et al. Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells. Blood 2008; 111: 369-375.
134. Kater AP, Dicker F, Mangiola M, Welsh K, Houghten R, Ostresh J et al Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. Blood 2005; 106: 1742-1748.
135. Carter BZ, Milella M, Tsao T, McQueen T, Schober WD, Hu W et al. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia 2003; 17: 2081-2089.
136. Lima RT, Martins LM, Guimaraes JE, Sambade C, Vasconcelos MH. Chemosensitization effects of XIAP downregulation in K562 leukemia cells. J Chemother 2006; 18: 98-102.
137. LaCasse EC, Cherton-Horvat GG, Hewitt KE, Jerome LJ, Morris SJ, Kandimalla ER et al. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res 2006; 12: 5231-5241.
138. LaCasse E, Morris S, Ward T, Cumings J, Robson L, Di Tullio K et al AEG 35156, a XIAP antisense oligonucleotide, suppresses XIAP levels in targeted tissues isolatedd from pre-clinical models and from patients. 97th American Association Cancer Research Annual Meeting. Washington, D.C. 2006.
139. Jolivet J, Dean E, Ward T, Denneny O, Jacob C, Goodege P et al. A phase I trial of AEG35156 (XIAP antisense) administered as 2-hour intravenous infusions in patients with advanced tumours. J Clin Oncol (Meeting Abstr) 2008; 26: 3541.
140. Ansell SM, Arendt BK, Grote DM, Jelinek DF, Novak AJ, Wellik LE et al Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 2004; 18: 616-623.
141. Tolcher AW, Antonia S, Lewis LD, Mita A, Mahany Jr J, Reddy NJ et al A phase I study of YM155, a novel survivin suppressant, administered by 168 h continuous infusion to patients with advanced solid tumors. J Clin Oncol (Meeting Abstr) 2006; 24: 3014.